

UNIVERSITY OF CALGARY CUMMING SCHOOL OF MEDICINE



Non-Invasive Brain Stimulation for OCD.



Alexander McGirr, MD PhD FRCPC June 22nd, 2022





I am a founder of MCGRx Corp and Salvostim Development Corp, and have filed provisional patent filings related to rTMS for depression and OCD.

Objectives

- 1. Understand the basic mechanisms of repetitive transcranial magnetic stimulation.
- 2. Identify the primary safety considerations for repetitive transcranial magnetic stimulation.
- 3. Know how to coordinate care during repetitive transcranial magnetic stimulation.

Disclaimer

- The mandate for the AHS rTMS program is major depressive disorder.
- I am not aware of private clinics or other resources that are providing TMS for OCD
 - The McGirr lab at the University of Calgary is running a clinical trial of TMS for OCD.

Obsessive Compulsive Disorder

- 3% population
- Obsessions
 - Intrusive thoughts, urges or mental images
- Compulsions
- 40-60% of patients do not fully respond to available treatments

Repetitive Transcranial Magnetic Stimulation for OCD

• In August 2018, the FDA approves repetitive transcranial magnetic stimulation (TMS) for OCD

FDA NEWS RELEASE

FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder

		_					
	f Share	🎔 Tweet	in Linkedin	🔁 Email	🖨 Print		
For Immediate Release:	August 17,	2018					
							Español
Today, the U.S. Food	l and Drug	Admini	stration p	ermitted	marketing	; of the Br	ainsway
Deep Transcranial M	Iagnetic St	imulatio	on System	for treat	ment of ob	sessive co	ompulsive
disorder (OCD).							
"Transcranial magne	etic stimula	ation has	s shown it	s potenti	al to help p	oatients su	uffering from
depression and head	laches," sai	d Carlos	s Peña, Ph	.D., M.S.	, director o	of the Divi	sion of
Neurological and Ph	ysical Med	icine De	vices in th	ne FDA's	Center for	Devices a	ind
Radiological Health.	"With tod	ay's mai	keting au	thorizati	on, patient	s with OC	D who have
not responded to tra	ditional tre	eatment	s now hav	e anothe	r option."		

What is Transcranial Magnetic Stimulation?

Transcranial Magnetic Stimulation

A method of:

- Delivering electromagnetic pulses
- These have a corresponding electrical field

Electromagnetism











A Long History

- Silvanus P Thompson (1851-1916)
- Mathematics & electromagnetism
- 1910
 - Flickering lights even with eyes closed



- Jacques-Arsene d'Arsonval (1851-1940)
- Study of alternating currents
- 1936:
 - Magneto phosphenes



Stimulation of the cerebral cortex in the intact human subject

P. A. Merton & H. B. Morton

The National Hospital, Queen Square, London WC1N 3BG, UK



Fig. 1 Stimulation of the arm area of the motor cortex. The records shown are of action potentials from the contracting muscles in the forearm. Stimulation is at the start of the sweep. Four records are superimposed. The latency of responses was 16 ms. (Subject P.A.M.)

The First TMS Machine



Fig 1—Magnetic stimulator and coil.



Fig 2-Muscle action potentials recorded from surface electrodes over abductor digiti minimi resulting from magnetic stimulus applied to opposite motor cortex (latency of response 23 ms) (upper) and to ulnar nerve at elbow (latency of response 7 ms) (lower).

Basic Mechanisms of Repetitive Transcranial Magnetic Stimulation

Repetitive Transcranial Magnetic Stimulation (rTMS) and Theta-Burst Stimulation (TBS)

- Most established evidence base for noninvasive neurostimulation treatment for OCD.
- Protocols of patterned pulses drive synaptic plasticity at cortical targets.
- Leverage reciprocal connections with cortical and subcortical regions.



Modelling plasticity with TMS





Recruitment Curves and TMS Plasticity



What is rTMS indicated for?

- Major Depressive Disorder
- Migraine
- Obsessive Compulsive Disorder
- Smoking Cessation









H1-Coil for Major Depressive Disorder (MDD) **H7-Coil** for Obsessive-Compulsive Disorder (OCD) H4-Coil for Smoking Cessation

for Major Depressive Disorder (MDD)

















eNeura[®]



Risks of rTMS

- Seizure
 - 1:1,000-1:10,000
 - Previous seizures
 - Intracranial lesion
 - Traumatic brain injury
 - Alcohol use disorder
- Magnetic fields
 - Heat or move metal
 - Metal workers
 - Aneurysm clips
 - Cochlear implants
- Dental hardware is OK



Side Effects

- Common
 - Headaches 65%
 - Scalp tingling discomfort 60%
- Less common (<10%)
 - Nausea
 - Vertigo
 - Worsening insomnia
 - Fatigue



rTMS Safety

- Pulses are delivered relative to a personalized threshold
- Motor cortex
- Active and resting motor threshold (aMT and rMT)



rTMS Safety

- Motor threshold is a metric of cortical excitability
- Things that change cortical excitability:
 - Medications
 - Substances
 - Sleep
- Things that do not change cortical excitability:
 - Psychotherapy
 - Mood
 - Symptom changes



What makes rTMS work better or worse?

• Better:

- Not clear
- Likely dependent on the disorder
- Worse:
 - Benzodiazepines
 - Gabapentin/pregabalin
 - Anticonvulsants



A Circuit Level Treatment for OCD





Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial

Lior Carmi, Ph.D., Aron Tendler, M.D., Alexander Bystritsky, M.D., Eric Hollander, M.D., Daniel M. Blumberger, M.D., Jeff Daskalakis, M.D., Herbert Ward, M.D., Kyle Lapidus, M.D., Wayne Goodman, M.D., Leah Casuto, M.D., David Feifel, M.D., Noam Barnea-Ygael, Ph.D., Yiftach Roth, Ph.D., Abraham Zangen, Ph.D., Joseph Zohar, M.D.



- Multisite
- 2014-17
- 6 weeks
- Moderate severity OCD (YBOCS>=20)
- Failed serotonin reuptake inhibitor or cognitive behavioral therapy
- On an 'antidepressant' for 2 months or be getting cognitive behavioral therapy

Personalized symptom provocation

- 3-5 minute provocation "to activate the relevant neuronal circuit"
- Subjective distress 4-7/10

Transcranial magnetic stimulation

- 'Deep' TMS
- Foot motor threshold
- Targeting the medial prefrontal cortex
- 20Hz at 100% rMT
- 2s trains, 20 second intertrain interval (18min 20s)
- 2000 pulses/treatment









Contents lists available at ScienceDirect

Journal of Psychiatric Research

journal homepage: www.elsevier.com/locate/jpsychires



Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites

Yiftach Roth ^{a,b,*}, Aron Tendler ^{a,b,c}, Mehmet Kemal Arikan ^d, Ryan Vidrine ^e, David Kent ^f, Owen Muir ^g, Carlene MacMillan ^h, Leah Casuto ⁱ, Geoffrey Grammer ^j, William Sauve ^j, Kellie Tolin ^k, Steven Harvey ¹, Misty Borst ^m, Robert Rifkin ¹, Manish Sheth ⁿ, Brandon Cornejo ^o, Raul Rodriguez ^p, Saad Shakir ^q, Taylor Porter ^r, Deborah Kim ^s, Brent Peterson ^t, Julia Swofford ^u, Brendan Roe ^u, Rebecca Sinclair ^g, Tal Harmelech ^b, Abraham Zangen ^a



Interventions

- H7 coil medial PFC
- Heterogeneous
 - 20Hz
 - Intermittent theta burst stimulation
- Symptom provocation
- Up to 29 treatments



Real World Results



Real World Results

• 'Response' defined as 30% improvement on the YBOCS



What are we doing in the McGirr?

Repetitive Transcranial Magnetic Stimulation (rTMS) and Theta-Burst Stimulation (TBS)

- Most established evidence base for noninvasive neurostimulation treatment.
- Protocols of patterned pulses drive synaptic plasticity at cortical targets.
- Leverage reciprocal connections with cortical and subcortical regions.



Leveraging pharmacological adjuncts targeting the NMDA receptor to enhance the *physiological effect* of iTBS.



The University of Calgary is currently recruiting volunteers who have been diagnosed with Obsessive Compulsive Disorder for a treatment study evaluating the effect of pairing rTMS with a medication. rTMS is a non-invasive (does not enter the body) technique that is FDA approved as a treatment for OCD.

Who can participate?

What does this study involve?

- People with a diagnosis of Obsessive Compulsive Disorder
- People 18 65 years of age
- People with no major unstable medical problems
- This study involves a screen visit and 4 weeks of rTMS sessions (20 sessions).
- You will continue with current medication/therapy.
- Participants will be compensated for each assessment visit completed.

To learn more please contact our study team: Phone: (403) 210 6504 E-mail: jaeden.cole1@ucalgary.ca

This study has been reviewed by the University of Calgary Conjoint Health Research Ethics Board REB#: REB21-0265 Department of Psychiatry Mathison Centre for Mental Health Research & Education 3280 Hospital Dr. NW. Calgary, AB, T2N 426 here 2021

June 2021 Version 2.0